This newsletter is addressed primarily to organisations representing patients, consumers and healthcare professionals. It provides a summary of key information relating to medicines for human use published during the previous month by the European Medicines Agency.

Information is selected based on recommendations from consulted patients, consumers and healthcare professionals, and does not necessarily cover all relevant information published by the Agency.

To receive each new issue of the newsletter, please click here RSS feeds, choose 'Human medicines highlights newsletter' and then click on 'Subscribe to this feed'. Please note, in order to be able to view RSS feeds you need one of the following: a modern web browser; a web-based news reader or a desktop news reader. For a list of RSS readers please refer to our RSS guide and follow the instructions from the selected RSS reader in order to add our newsletter feed.

Information on medicines

Antivirals/anti-infectives

New medicines authorised

- **Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva** (efavirenz / emtricitabine / tenofovir disoproxil) generic of Atripla
  Treatment of HIV infection

- **Entecavir Mylan** (entecavir) generic of Baraclude
  Treatment of hepatitis B

New information on authorised medicines

- **Cubicin** (daptomycin) - extension to existing indication
  Treatment of bacterial infections: complicated skin and soft-tissue infections, right-sided infective endocarditis (infection of the lining or the valves of the right side of the heart) and bacteraemia (infection of the blood)

- **Pegasys** (peginterferon alfa-2a) - extension to existing indication
  Treatment of chronic hepatitis B and C
Cancer

New medicines authorised

- **Bavencio** (avelumab) - Treatment of Merkel cell carcinoma (skin cancer)

New information on authorised medicines

- **Alecensa** (alectinib) - extension to existing indication - Treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer
- **Faslodex** (fulvestrant) - new indication - Treatment of breast cancer
- **Zytiga** (abiraterone acetate) - extension to existing indication - Treatment of prostate cancer

Dermatology

New medicines authorised

- **Bavencio** (avelumab) - Treatment of Merkel cell carcinoma (skin cancer)
- **Dupixent** (dupilumab) - Treatment of atopic dermatitis (inflammation of the skin)

New information on authorised medicines

- **Cubicin** (daptomycin) - extension to existing indication - Treatment of bacterial infections: complicated skin and soft-tissue infections, right-sided infective endocarditis (infection of the lining or the valves of the right side of the heart) and bacteraemia (infection of the blood)

Diabetes

New information on authorised medicines

- **Bydureon** (exenatide) - change in indication - Treatment of diabetes mellitus

Haematology

Safety communication update

- Review of **hydroxyethyl starch (HES) containing medicinal products** - review started (studies show low adherence to restrictions aimed at reducing risks of kidney injury and death) - Used for the management of hypovolaemia (low blood volume) caused by acute (sudden) blood loss

Key to symbols used

- O Orphan medicine
- G Generic medicine
- B Biosimilar medicine
- C Conditional approval
- E Exceptional circumstances
HIV

New medicines authorised

- **Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva** *(efavirenz / emtricitabine / tenofovir disoproxil)*
  
  Generic of Atripla
  
  Treatment of HIV infection

Immune system

Positive CHMP opinions on new medicines

- **Tacforius** *(tacrolimus)*
  
  Generic of Advagraf
  
  Used for prevention and treatment of transplant rejection

New medicines authorised

- **Dupixent** *(dupilumab)*
  
  Treatment of atopic dermatitis (inflammation of the skin)

Metabolic disorders

New medicines authorised

- **Nitisinone MDK (previously Nitisinone MendeliKABS)** *(nitisinone)*
  
  Generic of Orfadin
  
  Treatment of tyrosinaemia type 1 (HT-1)

Nervous system

Safety communication update

- Review of **Zinbryta** *(daclizumab)* - PRAC recommendation (to be used only in a restricted patient group, with strict liver monitoring)
  
  Treatment of multiple sclerosis

Respiratory system

New information on authorised medicines

- **Alecensa** *(alectinib)*
  
  Extension to existing indication
  
  Treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer

Rheumatology

New medicines authorised

- **Febuxostat Mylan** *(febuxostat)*
  
  Generic of Adenuric
  
  Treatment of hyperuricaemia (high levels of uric acid in the blood)
Other medicines

New medicines authorised

- **Cuprior** (trientine)
  Treatment of Wilson’s disease (rare autosomal recessive inherited disorder)

Safety communication update

- Review of flupirtine-containing medicinal products (flupirtine) - review started (medicines are being used outside current restrictions and cases of liver damage have been reported)
  Used as an analgesic (for pain relief)

Medicines under additional monitoring

- Updated list of medicines under additional monitoring

Other information

Guidelines

Guidelines open for consultation

- Reflection paper on the use of extrapolation in the development of medicines for paediatrics
  Deadline for comments: 14 January 2018

- Draft guideline on clinical investigation of recombinant and 4 human plasma-derived factor VIII products
  Deadline for comments: 31 January 2018

- Draft guideline on core SmPC for human plasma derived and recombinant coagulation factor VIII products
  Deadline for comments: 31 January 2018

- Concept paper on the need for a paediatric addendum of the guideline on clinical investigation of medicinal products for the treatment and prophylaxis of venous
  Deadline for comments: 31 January 2018

- Draft guideline on the clinical evaluation of medicinal products indicated for the prophylaxis or treatment of respiratory syncytial virus (RSV) disease
  Deadline for comments: 30 April 2018

Adopted guidelines

- Requirements for quality documentation concerning biological investigational medicinal products in clinical trials
- ‘Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials’ - overview of comments
- Clinical investigation of medicinal products for the treatment of ankylosing spondylitis
- Guideline on good pharmacovigilance practices (GVP): Annex 1 - Definitions (Rev.4)
- Guideline on good pharmacovigilance practices (GVP): Annex V - Abbreviations (Rev.1)

Key to symbols used

- Orphan medicine
- Generic medicine
- Biosimilar medicine
- Conditional approval
- Exceptional circumstances
• Guideline on good pharmacovigilance practices (GVP): Module VIII – Post-authorisation safety studies (Rev.3)
• Guideline on good pharmacovigilance practices (GVP): Module IX – Signal management (Rev.1)
• Guideline on good pharmacovigilance practices (GVP): Module IX – Signal management (Rev.1) - comments received from public consultation
• Guideline on good pharmacovigilance practices (GVP): Module IX Addendum I – Methodological aspects of signal detection from spontaneous reports of suspected adverse reactions
• Guideline on good pharmacovigilance practices (GVP): Module IX Addendum I – Methodological aspects of signal detection from spontaneous reports of suspected adverse reactions - comments received from public consultation
• Guideline on good pharmacovigilance practices (GVP): Module XV – Safety communication (Rev.1)
• Guideline on good pharmacovigilance practices (GVP): Module XV – Safety communication (Rev.1) - comments received from public consultation
• Guideline on good pharmacovigilance practices (GVP): Annex II – Templates: Direct Healthcare Professional Communication (DHPC) (Rev.1)
• Guideline on good pharmacovigilance practices (GVP): Annex II – Templates: Communication Plan for Direct Healthcare Professional Communication (CP DHPC) - comments received from public consultation
• ICH guideline E18 on genomic sampling and management of genomic data - First version
• ICH E11(R1) step 5 guideline on clinical investigation of medicinal products in the pediatric population
• ICH Q11 Development and manufacture of drug substances (chemical entities and biotechnological/ biological entities)

Other scientific recommendations

Classification of advanced therapy medicinal products (ATMPs)

• Viable chondrocytes cultured within a 3D hydrogel
• Messenger RNAs (mRNAs) encoding immunostimulatory proteins catLIR4, CD40L and CD70 and tumour associated antigens (TAA) tyrosinase, gp100, MAGE A3, MAGE C2 and PRAME
• Nuclease resistant, synthetic double-stranded small interfering RNA (siRNA)
• Allogeneic human glial-restricted precursors
• Allogeneic human glial-restricted precursors
• Autologous adipose tissue-derived mesenchymal stem cells
• Human autologous keratinocytes
• Stromal vascular fraction cells
• Human umbilical cord blood-derived mesenchymal stem cells
• Human autologous chondrocytes

Key to symbols used

O Orphan medicine  Generic medicine  Biosimilar medicine  Conditional approval  E Exceptional circumstances
Scientific committee and working party activities

- Medicinal products for human use: monthly figures - October 2017
- Medicinal products for human use: monthly figures - September 2017
- CHMP - agendas, minutes and highlights
- CHMP - applications for new human medicines: November 2017
- CHMP - applications for new human medicines: October 2017
- CAT - agendas, minutes and reports
- COMP - agendas, minutes and meetings reports
- HMPC - agendas, minutes and meetings reports
- PDCO - agendas, minutes and meeting reports
- PRAC - agendas, minutes and highlights
- PRAC recommendations on safety signals

Other publications

- EMA Management Board: highlights of October 2017 meeting
- EMA work programme 2017 - updated
- EMA takes yet another step in public engagement with its first public hearing
- EMA’s procedural handling of safety review was complete and independent
- EMA’s Business Continuity Plan for Brexit published
- EMA publishes comments on Member States’ hosting bids
- EMA process for engaging in external regulatory sciences and process improvement research activities for public and animal health
- General Court finds no fault in 2011 appointment procedure of EMA Executive Director
- New action plan to foster development of advanced therapies
- Enabling science that works for patients - leaflet
- Engaging with patients - video
- Better labelling of excipients for safe use of medicines
- Unparalleled access to clinical data - one year on
- Data privacy in the age of big data
- Countdown to launch of new EudraVigilance System
- EU scientific opinion: how to assess progress on reduction of antimicrobial resistance and antimicrobial consumption
- How to develop vaccines and medicines that prevent and treat respiratory syncytial virus (RSV) infection

Key to symbols used

- O Orphan medicine
- Generic medicine
- Biosimilar medicine
- Conditional approval
- Exceptional circumstances
• Cystic fibrosis workshop - Registries initiative - June 2017 - meeting documents
• Multiple sclerosis workshop - Registries initiative - July 2017 - meeting documents
• EMA - Payer Community meeting - September 2017 - meeting documents

Events

• EMA Information Day on Measuring the Impact of Pharmacovigilance Activities - November 2017
• Data anonymisation workshop - November 2017
Explanation of terms used

- **Orphan medicine**
  A medicine intended for the treatment of a rare, serious disease.

- **Generic medicine**
  A medicine that is essentially the same as one that has already been authorised for use.
  (The latter is known as the ‘reference medicine’)

- **Biosimilar medicine**
  A biological medicine that is similar to another biological medicine which has already been authorised for use.
  (Biosimilar medicines are also known as ‘similar biological’ medicines)

- **Conditional approval**
  A medicine that fulfils an unmet medical need may, if its immediate availability is in the interest of public health, be granted a conditional marketing authorisation on the basis of less complete clinical data than are normally required, subject to specific obligations being imposed on the authorisation holder.

- **Exceptional circumstances**
  A medicine may be approved in some cases where the applicant cannot provide comprehensive data on the safety or efficacy of the medicine under normal conditions of use, due to exceptional circumstances such as ethical issues or the rarity of the disease concerned.

---

**Note on the centralised authorisation procedure**

To obtain a single marketing authorisation (licence) for a medicine that is valid in all Member States of the European Union (EU) – via a process known as the ‘centralised procedure’ – the company or person developing the medicine must submit an application to the European Medicines Agency.

The Agency’s Committee for Medicinal Products for Human Use (CHMP) carries out a scientific evaluation of the information contained in the application and prepares an opinion (scientific recommendation). The Agency transmits this (positive or negative) opinion to the European Commission, which then issues a Decision granting or refusing the marketing authorisation.

When the CHMP adopts a positive opinion on a medicine, the Agency publishes on its website a ‘summary of opinion’, in the first instance, followed by more detailed information in a ‘European public assessment report (EPAR)’ after the marketing authorisation has been granted.

**Visit our website**

Further information about the European Medicines Agency and the work it does is available on our website:


In particular, you may be interested in these links:

- About us
- Patients and carers
- Healthcare professionals
- European public assessment reports